The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer

International Journal of Cancer, 04/20/2012

Although the conventional separation of patients with KRAS wild–type versus KRAS mutant tumors did not have a significant impact on outcome parameters in the AIO KRK 0104–trial, this analysis demonstrates that markedly differing results are obtained when subtypes of KRAS and BRAF mutation are taken into account.

Print Article Summary Cat 2 CME Report